Alto Neuroscience, Inc. ANRO
As ofNov 20, 2026, 11:33 AM EST
- YTD
- +42.64%
- 1 year
- +79.43%
- Market cap
- 1.01B
- EPS (ttm)
- -2.32
- Shares out
- 40.11M
- Forward P/E
- -8.95
- YTD return
- +42.64%
- 1-year return
- +79.43%
- 50-day average
- 25.82
- 200-day average
- 24.89
- Enterprise value
- 737.94M
- Price / book
- 3.57
- Volume
- 68.24K
- Avg volume
- 611.30K
- Open
- 25.30
- Previous close
- 26.51
- Day's range
- 25.30 – 25.30
- 52-week range
- 12.51 – 37.48
- Beta
- 1.45
- Analysts
- Strong Buy
- Price target
- 38.67 (+52.3%)
- Earnings date
- Mar 15, 2027
Key statistics
- Free cash flow
- -50.34M
- Total cash
- 319.34M
- Total debt
- 18.02M
- Return on equity
- -46.65%
- Short % of float
- 16.60%
Fundamental scorecard
3 of 25 checks passed on ANRO’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 26.00
- Target (mean)
- 38.67
- Target (high)
- 60.00
- Strong buy0
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 15, 2027
Expected Mar 15, 2027. Consensus EPS estimate -0.655.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 15, 2027 | Dec 30, 2026 | -0.54 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.67354 | -0.54 | +0.13 | +19.83% |
| Aug 12, 2026 | Jun 30, 2026 | -0.73454 | -0.65 | +0.08 | +11.51% |
| May 13, 2026 | Mar 31, 2026 | -0.56 | -0.80 | -0.24 | -42.86% |
| Mar 16, 2026 | Dec 31, 2025 | -0.56 | -0.45 | +0.11 | +19.64% |
| Nov 12, 2025 | Sep 30, 2025 | -0.66 | -0.52 | +0.14 | +21.21% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | BTIG | reit | Buy | Buy |
| Oct 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 17, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2026 | Wedbush | main | Neutral | Neutral |
| Aug 13, 2026 | BTIG | main | Buy | Buy |
| May 18, 2026 | Baird | main | Outperform | Outperform |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- altoneuroscience.com
News
Your note
Sign in to keep a note on ANRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ETKIN AMIT | Chief Executive Officer | Stock Gift | May 13, 2026 | 833,949 |
| HANLEY MICHAEL CONICK JR. | Chief Operating Officer | Sale | Nov 17, 2026 | 0 |
| SMITH NICHOLAS CONRAD | President | Conversion of Exercise of derivative security | Oct 1, 2026 | 79,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alpha Wave Global, LP | 9.24% | 3,707,757 | 98.11M | Sep 29, 2026 |
| Blackrock Inc. | 6.80% | 2,726,106 | 72.13M | Sep 29, 2026 |
| Commodore Capital Lp | 6.79% | 2,723,196 | 72.06M | Sep 29, 2026 |
| EcoR1 Capital, LLC | 5.56% | 2,232,000 | 59.06M | Sep 29, 2026 |
| Perceptive Advisors Llc | 4.39% | 1,760,950 | 46.59M | Sep 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.24% | 1,701,913 | 45.03M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 1,011,881 | 26.77M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.09% | 836,522 | 22.13M | Sep 29, 2026 |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.87% | 347,904 | 9.21M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.86% | 346,618 | 9.17M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.74% | 298,273 | 7.89M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.72% | 287,033 | 7.59M | Aug 30, 2026 |
